Hyderabad Company Develops India’s first DCGI-Approved Vaccine Candidate, Gets Nod For Human Trials

India’s first COVID Vaccine

Hyderabad Vaccine major Bharat Biotech on Monday announced that it’s COVAXIN has become the country’s first COVID Vaccine. Candidate approved by the Drug Controller General of India(DCGI) and the first vaccine that has got the approval. Of the drug controller for phase1 and 2 human clinical trials. The company has been working on the vaccine in collaboration with the Indian Council of Medical Research (ICMR). And the national institute of Virology, Pune for some time.

The DCGI gave permission to the company to initiate phase1 and 2 human clinical trials after it submitted results. WhixGenerated from preclinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across the country in July, a company;s statement said.

Bharat Biotech developed COVAXIN at the company’s bio-safety level-3 containment facility in Hyderabad’s Genome Valley. After taking the strain of SARS-CoV-2, isolated at the NIV, Pune.

Announcing the breakthrough, Bharat Biotech CMD Krishna Ella said,” We are proud to announce COVAXIN, India’s first indigenous COVID vaccine. The collaboration with the ICMR and NIV was instrumental in the development of this vaccine. Proactive support and guidance from the Central Drugs Standard Control Organisation(CDSCO). Has enabled approvals to the projects. Our R&D and manufacturing teams worked tirelessly to deploy our proprietary technologies toward this platform.”

Krishna Ella

COVAXIN was evaluated in animals as per schedule Y guidelines of India and World Health Organisation. It was reported to be safe and immunogenic in all animals. We have now moved forward towards the clinical development of this vaccine,” Krishna Ella told.

Besides the speedy progress on the indigenous vaccine, Bharat Biotech is simultaneously working on nasal vaccine CoroFlu. Against Covid-19 in collaboration with American researchers of the University of Wisconsin, Madison, and is also leading a Csir-sanctioned project to develop human monoclonal antibodies as therapy for COVID infection.

Suchita Ella

“Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is commited to advancing vaccine development as a matter of national importance to demonstrate India’s strength in handling future panedemics,” company’s Joint MD suchitra Ella said.

Bharat Biotech has established an excellent track of innovation with over 140 global paatents and awide product portfolio of over 16 vaccines.

You can read more about the vaccine on the official website of Bharat Biotech by clicking me.

Here are some more blogs:-

  1. COVID-19 Vaccine Mass Production
  2. Home Quarantine
  3. Corona cases in New Delhi
  4. Ayush Kwath: Immunity Booster

Total Page Visits: 356 - Today Page Visits: 1